Back to results
US 10,300,071 B2Granted
Compositions and methods for inhibition of mycobacteria
AssigneeThe Texas A&M University System
InventorsManchi C M Reddy, James C. Sacchettini, Nian E. Zhou, Billy F. McCutchen
Life of this patent
Estimating the term…
Abstract
A composition comprising a drug selected from the group consisting of an arylphenoxypropionate derivative, an aryloxyphenoxyacetate derivative, an aryloxyphenylacetate derivative, a substituted quinol, or a salt, hydrate, or prodrugs thereof, or a combination thereof, in an amount and formulation sufficient to inhibit a mycobacterium is disclosed.
Claims18
A composition comprising:
- a drug comprising 2-{4-[(6-chloro-1,3-benzothiazol-2-yl)oxy]phenyl}-N-methylpropanamide, 1-{4-[(6-chloro-1,3-benzothiazol-2-yl)oxy]phenyl}-3-(propan-2-yl)urea, 1-{4-[(6-fluoro-1,3-benzothiazol-2-yl)oxy]phenyl}-3-(propan-2-yl)urea, or 2-{4-[(6-chloro-1,3-benzothiazol-2-yl)oxy]phenyl}-N-methoxypropanamide, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof in an amount and formulation sufficient to inhibit a mycobacterium expressing Acetyl-CoA carboxyltransferase β-subunit D6 (AccD6);
- and
- a pharmaceutically acceptable carrier.
A method of inhibiting a mycobacterium expressing Acetyl-CoA carboxyltransferase β-subunit D6 (AccD6) comprising:
- administering a composition comprising a drug, having the formula:
- wherein:
- R1 is selected from —OH, —OCH3, —NHOCH3, —NHCH3, and —NHCH(CH3)2 groups;
- R2 and R3 are both H or at least one of R2 and R3 is —CH3;
- and
- R4 is selected from a 1,3-benzothiazole-2-yl, 1,3-benzothiazole-2-yl substituted with a halogen or —OCH3 group, and quinoxaline-2-yl, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof to the mycobacterium in an amount and for a time sufficient to inhibit AccD6 in the mycobacterium.
3 more elements
Dependencies are inferred from the claim text.